Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ACTINIUM PHARMACEUTICALS, INC.

(ATNM)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Actinium Pharmaceuticals, Inc. Announces Safety Data from Phase 3 SIERRA Trial of Iomab-B

06/15/2021 | 08:45am EDT

Actinium Pharmaceuticals, Inc. announced safety data from its ongoing pivotal Phase 3 SIERRA trial of Iomab-B in patients with relapsed or refractory Acute Myeloid Leukemia (r/r AML) Iomab-B targets CD45, an antigen expressed on leukemia and lymphoma cancer cells and immune cells including bone marrow stem cells but not on cells outside of the blood forming or hematopoietic system. This allows high amounts of radiation to be delivered to the bone marrow via Iomab-B while sparing critical organs. As a result, statistically significant lower rates of sepsis were reported as well as lower rates of febrile neutropenia, mucositis and non-relapse transplant related mortality in patients receiving Iomab-B and bone marrow transplant (BMT) compared to patients that received salvage therapy and a BMT. In addition, patients who crossed over to receive Iomab-B and went to BMT after receiving salvage therapy but not achieving a complete response also had lower rates of sepsis, febrile neutropenia, mucositis and non-relapse transplant related mortality.


ę S&P Capital IQ 2021
All news about ACTINIUM PHARMACEUTICALS, INC.
09:02aACTINIUM PHARMACEUTICALS STOCK JUMPS : Atnm)
AQ
09/16ACTINIUM PHARMACEUTICALS : Completes Enrollment in the Pivotal Phase 3 SIERRA Trial of Iom..
AQ
09/15ACTINIUM PHARMACEUTICALS : Completes Enrollment in Phase 3 Trial of Iomab-B to Treat Leuke..
MT
09/15Actinium Pharmaceuticals, Inc. Completes Enrollment in the Pivotal Phase 3 SIERRA Trial..
CI
08/03ACTINIUM PHARMACEUTICALS : HC Wainwright Adjusts Actinium Pharmaceuticals' Price Target to..
MT
07/30ACTINIUM PHARMACEUTICALS : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND..
AQ
07/30Actinium Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter Ended Ju..
CI
06/29ACTINIUM PHARMACEUTICALS : Announces Inclusion in Russell Microcap Index
AQ
06/17ACTINIUM PHARMACEUTICALS : Awarded Patents in Europe, Japan for Antibody Radiation Conjuga..
MT
06/15Actinium Pharmaceuticals, Inc. Announces Safety Data from Phase 3 SIERRA Trial of Iomab..
CI
More news
Analyst Recommendations on ACTINIUM PHARMACEUTICALS, INC.
More recommendations
Financials (USD)
Sales 2021 1,02 M - -
Net income 2021 -22,3 M - -
Net Debt 2021 - - -
P/E ratio 2021 -7,50x
Yield 2021 -
Capitalization 173 M 173 M -
Capi. / Sales 2021 170x
Capi. / Sales 2022 11,2x
Nbr of Employees 32
Free-Float 98,5%
Chart ACTINIUM PHARMACEUTICALS, INC.
Duration : Period :
Actinium Pharmaceuticals, Inc. Technical Analysis Chart | ATNM | US00507W2061 | MarketScreener
Technical analysis trends ACTINIUM PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Last Close Price 8,10 $
Average target price 30,00 $
Spread / Average Target 270%
EPS Revisions
Managers and Directors
Sandesh Seth Chairman & Chief Executive Officer
Steve O'Loughlin Chief Financial Officer
Mark S. Berger Chief Medical Officer
Dale L. Ludwig Chief Scientific & Technology Officer
Avinash Desai Executive VP-Clinical Development & Operations
Sector and Competitors
1st jan.Capi. (M$)
ACTINIUM PHARMACEUTICALS, INC.0.38%158
GILEAD SCIENCES, INC.21.80%88 970
BIONTECH SE315.86%81 878
WUXI APPTEC CO., LTD.35.75%69 413
REGENERON PHARMACEUTICALS32.66%66 632
VERTEX PHARMACEUTICALS-21.44%48 168